Patient-derived d-MMR/MSI phenotype urachal cancer organoids for personalized drug screening
d-MMR/MSI phenotype UrC PDOs recapitulate the phenotypic and molecular features of their parental tumors, capturing critical heterogeneity. As such, they represent a valuable platform for reflecting treatment responses, investigating resistance mechanisms, and developing individualized therapeutic regimens.
Authors
- Kuangen Zhang (ORCID: https://orcid.org/0000-0003-4242-5667)
- Zhenting Zhang (ORCID: https://orcid.org/0000-0002-4847-5561)
- Rong Liu (ORCID: https://orcid.org/0009-0005-1327-112X)
- X. Angela Yao
- Ning Zhang
- Xinyi Li
Institutions
- Peking University (CN)
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Peking University First Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-03-05
- DOI
- https://doi.org/10.3389/fonc.2026.1773072
- Primary Topic
- Urinary and Genital Oncology Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China